An exosome-based liquid biopsy to simplify cancer management

Biopsomic SA

Incorporated

16.08.2019

Headquarters

Lausanne

Support

Oncologists currently lack a simple test to evaluate the risk of recurrence in the therapeutic management of colorectal cancer.
Biopsomic's innovative and patented liquid biopsy solution based on circulating exosomes proteomics aims to revolutionize the life of millions of patients every year.
Biopsomic's product consists in a proprietary prognostic score conducted in a centralized laboratory from a blood sample taken from a colorectal cancer patient.
The revenue will be generated by billing medical insurances or health networks in major markets such as Europe and the USA or through partnerships with local players.
Biopsomic aims at refining and developing ultimately other tests and cancer screening methods.